Syndicated News

This blog is still in BETA

We are aware of any formatting errors. These stories are automatically pulled from RSS feeds. Due to the automated nature of the post, some images may appear small, and some links may not be clickable until our staff has had the opportunity to manicure the postings. Thank you for understanding.

March 13, 2015

Baxter BioScience Announces Positive Phase III Results for BAX 817 ... - MarketWatch

March 13, 2015/

http://ift.tt/1L6RNnG Click to read full article...

Baxter BioScience Announces Positive Phase III Results for BAX 817 ...MarketWatchThe prospective, open-label, randomized, multicenter trial was designed to assess the safety and efficacy of BAX 817 in male patients ages 12 to 65 with hemophilia A or B with inhibitors over a 6-month period using on-demand therapy. The trial met its ...and more »

from Hemophilia - Google News http://ift.tt/1L6RNnG via IFTTT

Committee of Ten Thousand

ADVOCATES FOR PERSONS WITH HIV/AIDS, HEMOPHILIA, HCV, AND SICKLE CELL

MONITORING THE BLOOD SUPPLY AND PROTECTING PATIENT RIGHTS SINCE 1989

The Committee of Ten Thousand is a grass-roots, peer-led, education, advocacy and support organization. The majority of our constituency is persons with hemophilia who contracted HIV/AIDS from tainted blood products. We work in solidarity with all communities affected by the HIV/AIDS pandemic. COTT advocates for disenfranchised chronic disease communities, especially those communities dependent on a safe national blood supply. We are dedicated to the belief that persons with HIV/AIDS and all chronic diseases can lead productive and healthy lives.

Find us on Facebook

Our Facebook Page

Stay in the debate! Join our discussion group!

Stay up to date! Join the mailing list!